Oral Proteins and Peptides Market Size and Revenue Impact Study 2026 to 2035

What is Oral Proteins and Peptides Market Size?

Oral Proteins and Peptides Market Size is valued at USD 8.18 Bn in 2025 and is predicted to reach USD 54.3 Bn by the year 2035 at an 21.80% CAGR during the forecast period for 2026 to 2035.

Oral Proteins and Peptides Market Share & Trends Analysis Report, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target, Type of Mechanism of Action, By Region, and Segment Forecasts, 2026 to 2035

Oral proteins and peptides are therapeutic medicines made from short chains of amino acids, designed for oral administration to leverage their biological properties in treating various ailments. However, their bioavailability is limited due to degradation by digestive enzymes like proteases in the stomach and small intestine. Despite these challenges, the FDA's approval of several novel oral protein and peptide drugs demonstrates the industry's commitment to overcoming these obstacles. These innovative treatments provide a more convenient and comfortable alternative to injections or intravenous administration and hold the potential to revolutionize the treatment of diseases like diabetes and hormone deficiencies. As a result, the oral proteins and peptides market is rapidly evolving, driven by the ability to address unmet medical needs, improve patient compliance, and enhance bioavailability.

The U.S. Food and Drug Administration (FDA) implemented the 21st Century Cures Act to expedite the approval process for innovative drug delivery systems, including oral formulations of proteins and peptides. In 2023, the FDA recognized the potential of Oramed Pharmaceuticals' oral insulin capsule to address unmet needs in diabetes care and awarded it Fast Track Designation, allowing for faster development and more frequent interactions with regulatory reviewers. Such regulatory advancements are crucial in improving patient care and accelerating the availability of oral protein and peptide products, supporting market growth. Additionally, ongoing research in biotechnology is driving the discovery of new therapeutic proteins and peptides, expanding the pipeline of potential oral treatments. The rising prevalence of chronic conditions like diabetes, cancer, and hormonal disorders further increases the demand for effective and patient-friendly therapeutic options.

Competitive Landscape

Some of the Major Key Players in the oral proteins and peptides market are

• AstraZeneca
• Biocon Chiasma
• Generex Biotechnology
• Novo Nordisk A/S
• Allergan
• Oramed Pharmaceuticals
• Proxima Concepts
• Synergy Pharmaceuticals
• Tarsa Therapeutics
• Sanofi
• Hoffmann-La Roche Ltd
• Novo Nordisk A/S
• Abbvie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.P.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Swk Holdings
• R-Pharm Jsc
• Entera Bio Ltd.
• Proxima Concepts
• Astrazeneca Plc
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Market Segmentation

The oral proteins and peptides market is segmented based on the type of target disease indication, type of molecule, type of biological target, and type of mechanism of action. Based on the type of target disease indication, the market is divided into acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease, and type II diabetes. Based on the type of molecule, the market is divided into protein and peptide. Based on the type of biological target, the market is divided into GC-C, insulin receptor, oxalate, and others. Based on the type of mechanism of action, the market is divided into receptor stimulation, substrate degradation, and others.

The Type II Diabetes Segment is Expected to Have the Highest Growth Rate During the Forecast Period

Based on the type of target disease indication, the market is divided into acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease, and type II diabetes. Among these, the type II diabetes segment is expected to have the highest growth rate during the forecast period. Traditional diabetes treatments, like insulin injections, can be uncomfortable and inconvenient for patients, especially those requiring daily doses.

Oral formulations of proteins and peptides, such as oral insulin, offer a more patient-friendly alternative, significantly improving treatment compliance. Given the chronic nature of Type II Diabetes, the long-term use of medications creates a large and continuous demand for treatment options. Oral protein and peptide therapies for diabetes, especially insulin, cater to this extensive and growing patient population. With a rapidly increasing global prevalence, Type II Diabetes is one of the most common chronic diseases. According to the International Diabetes Federation, hundreds of millions of people are affected worldwide, driving the demand for effective and manageable treatments.

The Peptides Segment Dominates the Market

Based on the type of molecule, the market is divided into protein and peptide. Among these, the peptides segment dominates the market. Peptides are smaller than proteins, making them easier to formulate for oral delivery. Their smaller size allows them to more readily navigate the challenges of the gastrointestinal (GI) tract, such as enzyme degradation and absorption barriers. Peptide-based therapies tend to have shorter development timelines compared to protein-based drugs due to their simpler structure. This leads to faster regulatory approval and market entry.

Peptides have diverse biological activities and can be used to treat a variety of diseases, including metabolic disorders (like Type II Diabetes), gastrointestinal issues, and cancer. Their versatility and effectiveness make them attractive candidates for oral formulations. Compared to proteins, peptides generally have better stability in the GI tract and can be engineered to enhance bioavailability. New technologies, such as peptide modification and protective delivery systems, help improve their effectiveness in oral delivery.

North America Has the Largest Market Share During the Forecast Period.

The region’s well-established healthcare system and access to cutting-edge medical technologies support the development and adoption of novel therapeutic products, including oral proteins and peptides. This infrastructure also facilitates clinical trials and regulatory approvals, accelerating the market's growth. The U.S. Food and Drug Administration (FDA) provides clear regulatory pathways and programs, such as Fast Track and Breakthrough Therapy Designations, that encourage the development of innovative treatments, including oral proteins and peptides. These regulatory initiatives speed up the approval process, which positively impacts market growth.  The aging population in North America is more prone to chronic diseases, increasing the need for convenient and effective treatments. Oral protein and peptide therapies, which offer non-invasive alternatives to injections, are well-suited to this demographic, further driving market growth.

Recent Developments:

• In Mar 2024, Biocon declared that its complex formulation of Liraglutide (6 mg/ml solution for injection in pre-filled pen), submitted through its European partner Zentiva, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K. Type 2 Diabetes Mellitus is a condition in which the body does not make enough insulin or respond to it appropriately, resulting in excessively high blood sugar (glucose) levels. Liraglutide is a medication-device combination formulation used to treat this condition.

• In Dec 2023, Pfizer Inc. revealed the results of the Phase 2b clinical study (NCT04707313) that examined the oral glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate danuglipron (PF-06882961) in people who were obese but did not have type 2 diabetes. By showing a statistically significant change in body weight from baseline, the study achieved its main goal.

• In Sept 2023, EnteraBio signed a deal with OPKO Biologics, Inc. to collaborate on research. As per the agreement, OPKO has committed to providing its exclusive long-acting GLP-2 peptide and specific analogues of oxyntomodulin for the development of oral tablet formulations.

Oral Proteins and Peptides Market Report Scope :